drugset
drugset / Trial / NCT07620405

Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease

NCT07620405 ↗

Phase 3 Not yet recruiting 219 enrolled Minghui Pharmaceutical (Hangzhou) Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.

Timeline

Start
2027-07
Primary completion
2030-01
Completion
2031-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MHB018A Monoclonal antibody 450 mg Subcutaneous

Indications

endocrine exophthalmos